No exception for Agennix as sepsis claims another hopeful victim - talactoferrin
This article was originally published in Scrip
Shares of Agennix succumbed to their biggest percentage fall in more than two years in Frankfurt trading upon an announcement that it was halting the Phase II/III OASIS trial of its oral immunotherapy talactoferrin (recombinant human lactoferrin) for severe sepsis. The trial showed that talactoferrin plus standard of care had a greater 28-day all-cause mortality than standard of care alone. Talactoferrin is the company's lead programme, and Agennix declined 30% to €1.88 at the close of trading.